Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICING study: Isatuximab and Cemiplimab in relapsed or refractory NK/T-cell lymphoid malignancy
KCT0005949Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab, cemiplimab in natural killer/T-cell lymphoma (NKTL), sponsored by Sanofi. Started Jun 2021; status: recruiting.
02
Drugs
isatuximabcemiplimab
03
Conditions
natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on KCT0005949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005949.